Regulators in the EU have introduced new testing requirements for all medicines containing the antibiotic drug, rifampicin, to address concerns that they may be contaminated with cancer-causing nitrosamine impurities.
Rifampicin is a first-line treatment for tuberculosis and is also used for treating several other serious infections, including blood infections...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?